Replimune Group (NASDAQ:REPL) Releases Earnings Results, Beats Expectations By $0.24 EPS

Key Points

• Replimune beat earnings expectations: The company reported a quarterly loss of $0.54 per share, $0.24 better than the analyst consensus loss of $0.78.
• TUDRIQEV’s commercial launch is gaining early traction: More than 70% of 200 target accounts have been engaged, roughly 20 have added the therapy to their formularies, and over 15 institutions had written prescriptions within the first 20 business days. Broad payer coverage and a favorable NCCN recommendation further support the launch.
• Replimune ended the quarter with $307.8 million in cash, expected to fund operations for more than 12 months, while the stock rose 12.6% to $14.70 following the results.

Replimune Group (NASDAQ:REPL - Get Free Report) released its earnings results on Wednesday. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.24, FiscalAI reports.

Here are the key takeaways from Replimune Group's conference call:

• TUDRIQEV’s launch is showing early traction: More than 70% of the initial 200 target accounts have been engaged, approximately 20 have added the drug to formulary, and more than 15 institutions had written prescriptions within the first 20 business days.
• Replimune reported strong physician interest across academic, community, oncology, and interventional radiology settings, with both superficial and image-guided injections already being used. Management expects the number of accounts initiating patients could potentially double by year-end.
• Coverage appears to be broad and favorable: TUDRIQEV has a Category 2A NCCN recommendation, Medicare coverage, and commercial payer policies covering its label—including retreatment in appropriate cases—with a permanent J-code expected by April 2027.
• The company reported no product revenue in the fiscal second quarter because commercial shipments began in October; it will report initial product revenue in the fiscal third quarter but is not providing revenue guidance. TUDRIQEV’s list price is $450,000 per treatment course before discounts, with revenue recognized over multiple quarters in some cases.
• Replimune ended the quarter with $307.8 million in cash, including $141 million from an August offering, and expects funding to support operations for more than 12 months while investing in the launch, IGNYTE-3, and the REVEAL uveal melanoma study.

Replimune Group Trading Up 12.6%

NASDAQ REPL traded up $1.65 on Wednesday, reaching $14.70. 2,424,706 shares of the company were exchanged, compared to its average volume of 4,305,073. The business's fifty day moving average price is $13.45 and its 200 day moving average price is $9.21. The stock has a market capitalization of $1.38 billion, a P/E ratio of -4.67 and a beta of 0.93. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $16.33.

Insider Buying and Selling

In other news, CAO Andrew Schwendenman sold 7,632 shares of Replimune Group stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the transaction, the chief accounting officer owned 99,425 shares in the company, valued at $1,289,542.25. The trade was a 7.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,467.59. Following the transaction, the insider directly owned 224,215 shares in the company, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock valued at $1,038,364 in the last quarter. Corporate insiders own 5.40% of the company's stock.

Wall Street Analyst Weigh In

REPL has been the subject of several research reports. Leerink Partners upgraded Replimune Group from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $11.00 to $17.00 in a research note on Tuesday, August 4th. Wolfe Research raised Replimune Group to an "outperform" rating in a report on Tuesday, August 4th. Cantor Fitzgerald restated an "overweight" rating on shares of Replimune Group in a research report on Monday, October 5th. Wedbush raised Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price target on the stock in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. lifted their price target on Replimune Group from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 26th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Replimune Group has a consensus rating of "Moderate Buy" and a consensus price target of $12.00.

Replimune Group Company Profile

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company's approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.